Physician profile
Anna Strongin
NPI 1255621363
$4,498.72
in general payments reported to CMS, 2019-2025
31 companies · $1,494 in 2025
The $1,494 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $371 · 2020: $163 · 2021: $79.62 · 2022: $260 · 2023: $773 · 2024: $1,358 · 2025: $1,494.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,625.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,625.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,149.10 | 2019-2025 | Viberzi, Linzess, Mavyret |
| Pfizer INC. | $525.66 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $490.75 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Janssen Biotech, INC. | $422.85 | 2023-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $280.10 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Celgene Corporation | $226.57 | 2022-2024 | Zeposia |
| Madrigal Pharmaceuticals | $142.72 | 2024-2025 | Rezdiffra, Resmetirom |
| Lilly USA, LLC | $137.85 | 2024-2025 | Omvoh |
| Regeneron Healthcare Solutions, INC. | $133.71 | 2023-2025 | Dupixent |
| Intercept Pharmaceuticals, INC. | $122.18 | 2019-2024 | Ocaliva |
| Phathom Pharmaceuticals, INC. | $79.72 | 2024-2025 | Voquezna |
| Ferring Pharmaceuticals INC. | $79.24 | 2019-2025 | Clenpiq, Rebyota |
| Gilead Sciences, INC. | $77.26 | 2019-2025 | |
| Genzyme Corporation | $75.33 | 2024-2025 | |
| Ironwood Pharmaceuticals, INC | $63.33 | 2019-2024 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $61.49 | 2024 | Iqirvo |
| Qol Medical, LLC | $55.37 | 2023-2024 | Sucraid, Sucraid |
| Celltrion USA INC. | $50.10 | 2025 | Vegzelma |
| Endogastric Solutions, INC | $42.09 | 2022-2023 | Esophyx |
| Merck Sharp & Dohme LLC | $36.46 | 2020-2023 | Dificid, Zinplava |
| Aimmune Therapeutics, INC. | $36.25 | 2023 | |
| Ardelyx, INC. | $32.10 | 2025 | Ibsrela |
| Novo Nordisk INC | $26.08 | 2025 | Wegovy |
| Cumberland Pharmaceuticals, INC. | $25.76 | 2023 | Kristalose |
| Alnylam Pharmaceuticals INC. | $25.52 | 2024 | Givlaari |
| Fresenius Kabi USA, LLC | $21.77 | 2025 | Adalimumab-Aacf |
| Daiichi Sankyo INC. | $19.58 | 2022 | |
| Braintree Laboratories, INC. | $17.42 | 2025 | Sutab, Suflave |
| Ethicon US, LLC | $16.64 | 2020 | |
| Evoke Pharma, INC. | $13.07 | 2024 | |
| Allergan, INC. | $12.65 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Strongin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.